scholarly journals The role of histone lysine demethylases in cancer cells’ resistance to tyrosine kinase inhibitors

2019 ◽  
Author(s):  
Jasmine Cassar White ◽  
Perla Pucci ◽  
Francesco Crea
Keyword(s):  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Histone Lysine ◽  
Histone Lysine Demethylases

scholarly journals Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0213984
Author(s):  
Yun Jung Choi ◽  
Gun Min Park ◽  
Jin Kyung Rho ◽  
Sun Ye Kim ◽  
Gwang Sup So ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Igf Binding ◽  
Egfr Mutant ◽  
Igf Binding Protein

scholarly journals Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e81393 ◽  
Author(s):  
Yun Jung Choi ◽  
Gun Min Park ◽  
Jin Kyung Rho ◽  
Sun Ye Kim ◽  
Gwang Sup So ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
Igf Binding ◽  
Egfr Mutant ◽  
Igf Binding Protein

A REVIEW ON THE ROLE OF TYROSINE KINASE INHIBITORS AVAILABLE FOR THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA

2020 ◽  
Vol 7 (2) ◽  
pp. 205-211
Author(s):  
Kaynat Fatima ◽  
Syed Tasleem Raza ◽  
Ale Eba ◽  
Sanchita Srivastava ◽  
Farzana Mahdi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Protein Kinases ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

The function of protein kinases is to transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are linked to the initiation and development of human cancer. The recent development of small molecule kinase inhibitors for the treatment of different types of cancer in clinical therapy has proven successful. Significantly, after the G-protein-coupled receptors, protein kinases are the second most active category of drug targets. Imatinib mesylate was the first tyrosine kinase inhibitor (TKI), approved for chronic myeloid leukemia (CML) treatment. Imatinib induces appropriate responses in ~60% of patients; with ~20% discontinuing therapy due to sensitivity, and ~20% developing drug resistance. The introduction of newer TKIs such as, nilotinib, dasatinib, bosutinib, and ponatinib has provided patients with multiple options. Such agents are more active, have specific profiles of side effects and are more likely to reach the necessary milestones. First-line treatment decisions must be focused on CML risk, patient preferences and comorbidities. Given the excellent result, half of the patients eventually fail to seek first-line treatment (due to discomfort or resistance), with many of them needing a third or even further therapy lines. In the present review, we will address the role of tyrosine kinase inhibitors in therapy for chronic myeloid leukemia.

scholarly journals Potential role of tyrosine kinase inhibitors during primary HIV-1 infection

2017 ◽  
Vol 15 (5) ◽  
pp. 421-423 ◽  
Author(s):  
Juan Ambrosioni ◽  
Mayte Coiras ◽  
José Alcamí ◽  
José M. Miró
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Potential Role ◽  
Kinase Inhibitors ◽  
Hiv 1

scholarly journals Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

2006 ◽  
Vol 17 (8) ◽  
pp. 1185-1196 ◽  
Author(s):  
P. Schöffski ◽  
H. Dumez ◽  
P. Clement ◽  
A. Hoeben ◽  
H. Prenen ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

scholarly journals EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy

Oncotarget ◽  
2015 ◽  
Vol 6 (19) ◽  
pp. 17491-17500 ◽  
Author(s):  
Yun-Tian Li ◽  
Xiao-Jun Qian ◽  
Yan Yu ◽  
Zhen-Hua Li ◽  
Rui-Yan Wu ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Caspase 8 ◽  
Egfr Tyrosine Kinase ◽  
Egfr Tyrosine Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document